Uniqure NV at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Good morning and thank you for joining Guggenheim's genomic medicines and rare disease conference. I am Debjit, representing the Guggenheim therapeutics team. And it is my privilege to host uniQure's Chief Executive Officer, Matt Kapusta, for a fireside chat to kick off this two-day event. Thank you for your time, Matt.
Thanks for having us, Debjit.
Questions & Answers
Good morning. And so maybe we can start it off with sort of a broad thought process question here. You've been the CEO of uniQure for a little over five years now. How would you reflect on the company's progress as well as challenges during this time? And from driving shareholder value for the next three to four years or next one to three years, what should we be focused on?
Yes, it's a great question. I think that we've made
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |